Genzyme is a pharmaceutical company based in Cambridge, MA. In 2011, it was acquired for $20 billion by French pharma company Sanofi (Rooney, 2011). Thus, Genzyme is no longer a publicly-traded company, but it is run as an independent subsidiary. Sanofi made the purchase in part to renew its pipeline of new drug developments after experiencing a slowdown in new drug approvals, which means they haven't been developing drugs at the same rate they were able to in the past. The acquisition therefore increases Sanofi's R&D capabilities (Rooney, 2011). At the time of the acquisition, Genzyme had reported net income in the third quarter of $221.1 million, indicating that the company was quite profitable, and its year-over-year figures were impressive (Rooney, 2011). Since the deal, Sanofi has declared that the acquisition was a success and that the company believed Genzyme had added value to the French firm (Weisman, 2013). SWOT - Strengths

Genzyme has a number of strengths. The company is profitable, as can be inferred by the fact that it was profitable when it was purchased and Sanofi is pleased with the acquisition. This hints that Genzyme has only become more profitable since the purchase. Sanofi is well-financed, which should benefit Genzyme. Sanofi in FY2012 recorded revenues of €35.9 billion and net income of €4.9 billion (MSN Moneycentral, 2013). The company has ample cash and liquidity on its balance sheet. If Genzyme needs funding for research and development, Sanofi is in a position to deliver that funding, which is an advantage for Genzyme.

Another strength is that Genzyme has a good stable of drugs. A new drug, Lemtrada, has received approval in Europe since the purchase and is expected to win approval from the FDA as well. This drug was one of the focal points of the negotiations between the two companies (Weisman, 2013). Lemtrada treats multiple sclerosis. While Lemtrada has received some approval from the FDA, the regulatory authority does still have some concerns about the drug's effectiveness (Frieden, 2013).

Weaknesses

Although Genzyme is a strong company, it is possible that its position within Sanofi can be seen as a weakness. Not being independent, Genzyme does not have 100% control over its operations,...

This can be a detriment to the company, especially if it starts to affect recruitment.
Another weakness at Genzyme has had problems, especially in 2009, with respect to its manufacturing processes. These issues including having one of its plants shut down due to infection with Vesivirus 2117, the second time this virus had struck a Genzyme facility. While it appears that these issues are behind the company, that it happened so recently is definitely a weakness. The plant that was shut down is still not operating at full capacity (DePalma, 2010).

Opportunities

With the new ownership the company has some opportunities. First, having French ownership gives Genzyme better access to the European market. While it always had regulatory access, perhaps its distribution channels were not as effective. Sanofi is in a position to give better worldwide distribution to Genzyme's drugs.

Another key opportunity is with new drug development. This is the lifeblood of any pharmaceutical company Genzyme already had strong drug development capabilities, but the added financial strength and access to development talent that comes with being part of Sanofi should enhance the company's drug development capabilities. Without a new drug pipeline, no pharma company with a development business model can survive, but Genzyme seems poised to take advantage of this opportunity.

Threats

Conversely, there are a number of threats that challenge Genzyme. The first of these is the regulatory environment. Right now there are considerable pressures that can be brought to bear. First, key markets like the U.S. And EU are governed by strict regulations regarding new drugs. The result of this is a high cost of drug development, and the companies are entirely at the whim of the regulators as to which products will allowed onto the market and which will not. Thus, the regulators are a significant threat. Even with approval, for example with Lemtrada, if it turns out in subsequent research that it is not effective, the FDA could revoke its approval.

Another threat in the regulatory environment comes in particular in the U.S. market, where the Affordable Care Act is seeking to drive down drug costs as one of its methods of lowering the cost of…